Adherence to drug treatment among schizophrenic patients in Jigawa State, Nigeria

Published: September 9, 2019
Abstract Views: 740
PDF: 421
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


  • Ado Shehu Department of Nursing Sciences, Faculty of Basic Health Sciences, Maryam Abacha American University of Niger, Maradi, Niger; Department of Nursing Services, Federal Medical Centre Birnin Kudu, Nigeria.
  • Saleh Ngaski Garba Department of Nursing Sciences, Faculty of Allied Health Sciences, Ahmadu Bello University, Zaria, Nigeria.
  • Emmanuel Ejembi Anyebe Department of Nursing Sciences, Faculty of Health Sciences, National Open University of Nigeria, Abuja, Nigeria.
  • Mb Tukur Department of Nursing Sciences, Faculty of Allied Health Sciences, Ahmadu Bello University, Zaria, Nigeria.
  • Hayat Gomma Department of Nursing Sciences, Faculty of Allied Health Sciences, Ahmadu Bello University, Zaria, Nigeria.

Schizophrenia is among the most common psychiatric disorders, affecting approximately 1% of the world’s population and is among the leading cause of disability. Adherence to drug therapy is associated with favourable clinical outcomes and good quality of life among schizophrenic patients undergoing treatment. This study assessed the prevalence and factors responsible for adherence/ non-adherence to drug treatment among schizophrenic patients in Jigawa State. We used a descriptive hospital-based cross-sectional study design and recruited three hundred and ninety- nine patients using multi-stage sampling technique. The mean and standard deviation of age of the respondents was 42.3±11.2. The level of drug adherence was 47.1%. On bivariate analysis, cost of treatment, types of treatment, side effects, and effects of treatment on the performance were found to be associated with low adherence of drugs treatment (P<0.05). On adjusting for confounding effect using logistic regression analysis, the cost of treatment of more than one thousand naira per day (AOR=3.00, 95%CI=2.75-8.83) and presence of side effects (AOR=4.01, 95%CI=1.45-16.09) were found to be predictors of non-adherence to drug treatments. Supervised community treatment, behavioural change communications along with community mental health care financing were recommended in order to increase access and decrease non-adherence to drugs.

Afolayan, J. A., & Peter, I. O. (2015). Prevalence of Schizophrenia among Patients Admitted Into a Nigeria Neuro-Psychiatric Hospital. IOSR Journal of Dental and Medical Sciences. 2015;14(6), 9–14.

Mahaye S, Mayime T, Nkosi, S, Mahomed, F. N, Pramlal, J, Setlhabana, O, & Oosthuizen, F. Medication adherence of psychiatric patients in an outpatient setting. Afr.J.Pharm.Pharmacol. 2012, 6(9), 608–612. DOI:

Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006, 67: 453-460 DOI:

Yang J, Kloud Y.H, Paik JW, Lee MS, Han C, Joe SH, Jung IK, Jung HG, Kim SH. (2012). Symptom severity and attitudes towards medication: impacts on adherence in outpatients with schizophrenia. Schizophrenia.2012; 134(2-3):226-31.

Kassis IT, Ghuloum S, Mousa H, Bener A. Treatment noncompliance of psychiatric patients; are patients satisfied from their psychiatrist? Br. J. Med. Med. Res. 2014; 4(2):785 - 796.

Ibrahim A.W, Yahya S, Kwajafa S.P, Abba W.M, Garkuwa A , Sale Shehu. Prevalence and predictors of sub-optimal medication adherence among patients with severe mental illnesses in a tertiary psychiatric facility in Maiduguri, North-eastern Nigeria. Pan African Medical Journal. 2015; 21:39 doi:10.11604/pamj.2015.21.39.6664 DOI:

Abiodun A, Owoeye O, Adebayo E, Adewale O.C. Prevalence and correlates of poor medication adherence amongst psychiatric outpatients in Southwestern Nigeria. General hospital psychiatry. 2009; 31(2):167-74. DOI:

Oluseun P. I, Andrew T. O, Olatunji F. A, Njideka U. O. Medication adherence among Nigerians with schizophrenia: correlation between clinico-demographic factors and quality of life. Mental Illness. 2017; 9:6889

Lacro JP, Dunn LB, Dolder CR, Leckband SG, Veste DV. Prevalence of and risk factors for medication non-adherence in Patients with Schizophrenia: a comprehensive review of recent literature. Jackson C. Psychiatry. 2002; 63(10): 892-909.

Bonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects to adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012; 12:20. DOI:

Hayness I. S, Kaiser W, Priebeb S, Barr W, Hoffmann K, Isermann M, Huxley, P. Profiles of subjective quality of life in schizophrenic in- and outpatients samples. Pyschiatric Research. 1997; 153-166. DOI:

Omranifard V, Karahmadi M, Jannesari Z, Maracy, M. Efficacy of modified compliance therapy for schizophrenia patients. Journal of Research in Medical Sciences. 2012; 17(SUPPL.2), S258–S263.

Whitney N, Glazier R. Community Health Factors Affecting Medication Adherence among the Homeless : A Qualitative Study of Patients’ Perspectives. University of Toronto MedicalJournal. 2000; 82(1)6–9.

Kazadi, N. J. B., Moosa, M. Y. H., & Jeenah, F. Y. (2008). articles on Factors associated with relapse in schizophrenia. Psychiatry. 2008; 14(2): 53-55.

Smith KW, Larson MJ. Quality of life assessments by adult substance abusers receiving publicly funded treatment in Massachusetts. American Journal of Drug Alcohol Abuse. 2010; 29(2): 323-335.

Skantze K, Malam U, Dencker S.J, May P.R, Corrigan P. Comparison of quality of life with standard of living in schizophrenic outpatients. Brit J Psychiatry. 2012; 161: 797-801. DOI:

Schrier, A.C., Van de Wetering, B.J.M., Mulder, P.G.H. & Selten, J.P. Point Prevalence of Schizophrenia in Immigrant groups in Rotterdam: Data from Outpatient facilities. Enr. Psychiatry. 2001; 16:162-166

Hayhurst, K. P., Drake, R. J., Massie, J. A., Dunn, G., Barnes, T. R. E., Jones, P. B., & Lewis, S. W. (2014). Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. European Psychiatry; 29(3): 191–196. DOI:

Rababa, S. (2013). Partial adherence with Antipsychotics Medications and factors related to Medication Relapse in Jordanian patient. European Scientific Journal. 2013; 9(3): 20–29.

Griffith, T. H. Caregiver Views on Medication Treatment for Persons with Schizophrenia in a Cultural Context Caregiver Views on Medication Treatment for Persons with Schizophrenia. Transcultural Psychiatry. 2012; 4(2): 23-26

Shehu, Ado, Saleh Ngaski Garba, Emmanuel Ejembi Anyebe, Mb Tukur, and Hayat Gomma. 2019. “Adherence to Drug Treatment Among Schizophrenic Patients in Jigawa State, Nigeria”. Annals of African Medical Research 2 (1).


Download data is not yet available.